Washington, D.C. – Congressman Michael C. Burgess, M.D. (R-TX), released the following statement after voting in support of H.R. 2630, the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act.
"This is a critical reauthorization that is imperative to maintaining our nation’s efforts to address the opioid epidemic." said Burgess. "I do wish this bill was authorized to May 6, 2022 and not just until the end of this September. It is important that we do not let this authorization lapse for the imminent threat it is to Americans. The temporary emergency rescheduling of fentanyl analogues to Schedule I is a necessary tool for the Drug Enforcement Administration to work with other agencies and law enforcement officials to address the threat of illicit fentanyl. I am grateful for the support it received in the House and encourage the Senate to quickly pass this vital legislation."